Skip to main content

Health

Oxford BioMedica PLC OXB View profile

OXB lines up commercial supply role for Aura's eye cancer drug

The image depicts a laboratory setting featuring a tablet displaying molecular graphics alongside scientific equipment, including vials and a micropipette. The laboratory counter h — Credit: AI-generated (ChatGPT)
AI-generated (ChatGPT)

OXB, the Oxford-based cell and gene therapy manufacturer, is preparing to make a potential eye cancer treatment at commercial scale for Aura Biosciences, a US biotechnology company.

The drug, belzupacap sarotalocan, known as bel-sar, is in Phase 3 trials, the final stage of testing before companies can apply for regulatory approval.

OXB has begun transferring the manufacturing process into its plant in Durham, North Carolina, which has been approved by the US Food and Drug Administration (FDA).

That work is designed to prepare for process performance qualification (PPQ), a series of production runs that show regulators a drug can be made consistently at commercial scale.

It should then lead into full commercial production if bel-sar is approved.

OXB said the work would support Aura's late-stage trials, any future regulatory filings and the eventual launch of the drug.

Neither company disclosed the financial terms.

A step into a new market

The deal takes OXB into a new type of product.

Bel-sar is a virus-like drug conjugate (VDC), which uses particles modelled on a virus to carry a cancer-killing drug to tumour cells.

OXB has spent more than 30 years making viral vectors, modified viruses used to deliver genetic material in cell and gene therapies.

It said VDCs were an adjacent market that sat close to its core expertise.

The Durham site can produce the active drug and fill it into vials, so both steps take place in one location.

Early development work is being handled at OXB's process and analytical development site in Bedford, Massachusetts.

Partnership already under way

The two companies agreed the partnership earlier this year, and Aura disclosed it in its third-quarter update before OXB confirmed it today.

OXB, a FTSE 250 company, works as a contract development and manufacturing organisation (CDMO), producing therapies on behalf of drug developers.

It runs sites in Oxfordshire, Lyon and Strasbourg in France, and in Massachusetts and North Carolina.

"As Aura advances bel-sar through Phase 3 development, a well-characterised and robust manufacturing process is critical," said Sebastien Ribault, chief business officer at OXB.

He said the partnership showed OXB could provide "a world-class service offering" in VDC manufacturing.

The release is thin, so this runs to about 330 words rather than the full 350 rather than padding it out.